Page last updated: 2024-10-25

nonivamide and Low Back Ache

nonivamide has been researched along with Low Back Ache in 2 studies

nonivamide: has effect on sensory neurons
nonivamide : A capsaicinoid that is the carboxamide resulting from the formal condensation of the amino group of 4-hydroxy-3-methoxybenzylamine with the carboxy group of nonanoic acid. It is the active ingredient in many pepper sprays.

Research Excerpts

ExcerptRelevanceReference
"Until now, nonivamide/nicoboxil ointment has not been tested in a randomized trial for the treatment of acute non-specific low back pain."9.22Efficacy and safety of nicoboxil/nonivamide ointment for the treatment of acute pain in the low back - A randomized, controlled trial. ( Gaubitz, M; Holm, C; Pisternick-Ruf, W; Richter, E; Schiffer, T; Weiser, T, 2016)
"Until now, nonivamide/nicoboxil ointment has not been tested in a randomized trial for the treatment of acute non-specific low back pain."5.22Efficacy and safety of nicoboxil/nonivamide ointment for the treatment of acute pain in the low back - A randomized, controlled trial. ( Gaubitz, M; Holm, C; Pisternick-Ruf, W; Richter, E; Schiffer, T; Weiser, T, 2016)
"The aim of the present study was to evaluate the therapeutic potential of local capsaicinoid (EMSPOMA(®) cream) treatment on chronic low back pain in patients with degenerative spine diseases and to investigate the possible mechanism of action of the therapy."5.19Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma. ( Bagoly, T; Boros, M; Helyes, Z; Horváth, K; Kemény, A; Kilár, F; Pintér, E; Sándor, V; Szolcsányi, J, 2014)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Horváth, K1
Boros, M1
Bagoly, T1
Sándor, V1
Kilár, F1
Kemény, A1
Helyes, Z1
Szolcsányi, J1
Pintér, E1
Gaubitz, M1
Schiffer, T1
Holm, C1
Richter, E1
Pisternick-Ruf, W1
Weiser, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-centre, Double-blind, Randomised, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Topically Applied Hyperemisation-inducing Ointment (2cm Ointment Line Per Application; up to 3 Times Daily for up to 4 Days) Containing 2[NCT01708915]Phase 3805 participants (Actual)Interventional2012-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Difference Between Baseline Pain Intensity and Average Pain Intensity on the Last Individual Treatment Day

Average pain intensity was assessed in the evening of days 1, 2, 3 and 4 on a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain possible). The last individual treatment day is the last day with diary-recorded ointment application. Means were adjusted for centre effect and baseline value. (NCT01708915)
Timeframe: Baseline and 1 to 4 days

Interventionunits on a scale (Least Squares Mean)
Placebo-1.884
Nicoboxil-2.371
Nonivamide-3.074
Nicoboxil/Nonivamide-3.540

Pain Intensity Difference (PID) Between Pre-dose Baseline and 4 Hours After First Application

Pain intensity was assessed on a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain possible) at pre-dose baseline and 0.5, 1, 2, 3 and 4 hours after first ointment application. Means were adjusted for centre effect and baseline value. (NCT01708915)
Timeframe: Baseline and 4 hours after first ointment application

Interventionunits on a scale (Least Squares Mean)
Placebo-0.650
Nicoboxil-0.968
Nonivamide-1.641
Nicoboxil/Nonivamide-1.699

Pain Intensity Difference (PID) Between Pre-dose Baseline and 8hours After First Application

Pain intensity (PI) was assessed on a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain possible) at pre-dose baseline and 0.5, 1, 2, 3, 4, 6 and 8 hours after first ointment application. Means were adjusted for centre effect and baseline value. (NCT01708915)
Timeframe: Baseline and 8 hours after first ointment application

Interventionunits on a scale (Least Squares Mean)
Placebo-1.049
Nicoboxil-1.428
Nonivamide-2.252
Nicoboxil/Nonivamide-2.410

Patient Assessment of Efficacy on the Last Individual Treatment Day

Patient assessment of efficacy was assessed on a 4-point verbal rating scale (VRS, 0 = 'poor', 1 = 'fair', 2 = 'good', 3 = 'very good' relief of the patients' low back pain) in the evening of days 1, 2, 3 and 4. The last individual treatment day is the last day with diary-recorded ointment application (NCT01708915)
Timeframe: 1 to 4 days

,,,
Interventionparticipants (Number)
Very goodGoodFairPoorMissing
Nicoboxil196720941
Nicoboxil/Nonivamide508820422
Nonivamide348527520
Placebo947221251

Trials

2 trials available for nonivamide and Low Back Ache

ArticleYear
Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma.
    Neuropeptides, 2014, Volume: 48, Issue:6

    Topics: Administration, Cutaneous; Aged; Analgesics; Capsaicin; Female; Humans; Low Back Pain; Male; Middle

2014
Efficacy and safety of nicoboxil/nonivamide ointment for the treatment of acute pain in the low back - A randomized, controlled trial.
    European journal of pain (London, England), 2016, Volume: 20, Issue:2

    Topics: Acute Pain; Adolescent; Adult; Aged; Capsaicin; Double-Blind Method; Drug Combinations; Female; Huma

2016